- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.
EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles
EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance
EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones addresses strategies to reduce barriers to medication access, with Callahan emphasizing the role of clinical pathways in streamlining ESR1 mutation testing documentation. Vidal discusses oral selective estrogen receptor degraders (SERDs) in development, highlighting differences in toxicity profiles among agents and expressing anticipation for these options in clinical practice. Gradishar explores the evolving landscape of new agents. The discussion emphasizes the need for differentiation and efficacy data among emerging drugs, which promise an exciting era with expanded treatment options for patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) breast cancer. Concluding the peer exchange, each expert shares their final thoughts, celebrating the current and upcoming advancements in ER+/HER– breast cancer therapeutics, focusing on their efficacy, tolerability, and potential to improve patient outcomes and quality of life. Stay informed about the evolving landscape of breast cancer treatments and explore the promising future of tailored therapies.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
